improving patient outcomes in urothelial carcinoma with novel antibody–drug conjugates
Published 2 years ago • 162 plays • Length 40:12Download video MP4
Download video MP3
Similar videos
-
31:39
the evolving role of antibody-drug conjugates in the treatment of urothelial carcinoma
-
1:32
antibody-drug conjugates in urothelial carcinoma
-
1:58
what’s next for antibody drug conjugates in urothelial carcinoma?
-
1:14:45
advancing bladder cancer care with novel therapeutics
-
2:30
the future of antibody-drug conjugates in urothelial cancer
-
56:13
advanced/metastatic urothelial carcinoma: understanding novel immunotherapy maintenance strategies
-
57:18
translating progress with immunotherapies and targeted agents into improved outcomes in tnbc
-
55:13
advanced/metastatic urothelial carcinoma: understanding novel immunotherapy maintenance strategies
-
53:15
will new antibody drug conjugates cure bladder cancer?
-
28:30
high grade non muscle invasive bladder cancer: stages and treatment including bcg
-
8:29
#uromigoslive24 adcs in uc panel part 4: novel adcs including her3 and novel nectin-4
-
1:10:42
revolutionizing solid tumor treatment: unleashing the potential of antibody-drug conjugates
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
1:39
the future of antibody-drug conjugates in urothelial carcinoma
-
1:08:04
understanding the evolving treatment landscape in bladder cancer
-
51:59
facilitating progress in the treatment of sclc
-
0:44
antibody-drug conjugates for advanced bladder cancer
-
1:03:24
bladder cancer: understanding immune-, targeted-, and antibody-based models for patient care
-
1:31:33
maximizing the role of adcs in urothelial carcinoma
-
31:19
new and emerging therapeutic strategies in bladder cancer
-
1:32:29
candid conversations on modern urothelial cancer management
-
48:40
taking aim with the next wave of antibody–drug conjugates in nsclc to address unmet needs